Sagtec Global Limited Strengthens Smart Property Development Collaboration Following Stateight Sdn Bhd’s Industry Recognition 
TruMerit and Credivera Issue First Verifiable Digital Credentials for Global Healthcare Professionals 
MK International Achieves ASEAN & Asia Records for Proprietary Quantum Molecular Technology Spray Series 
American Aires Inc. Announces Updates on Annual Filings, Litigation and Listing Matters, Cease Trade Order, and 2024 Financial Statements Cellectis Announces Participation in Five Investor Conferences
NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) — Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH:…
Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement
Shares of Aadi to commence trading on the Nasdaq Capital Market on August 27, 2021…
Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.
Kathleen Sebelius Chair of Humacyte’s Board of Directors Dr. Laura Niklason Founder, President & CEO…
Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
Innovent will provide proprietary antibodies for selected tumor targets and Bolt will provide its proprietary…
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa., Aug. 26, 2021 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage…
Erasca Reports Second Quarter 2021 Financial Results and Business Updates
Successfully closed $345 million upsized IPO in July 2021 On track to initiate multiple HERKULES…
Mountain Valley MD Holdings to Graduate to OTCQX Best Market, Updates Broader Up-Listing Strategy
TORONTO, Aug. 26, 2021 (GLOBE NEWSWIRE) — Mountain Valley MD Holdings Inc. (the “Company” or…
Kane Biotech Announces Second Quarter 2021 Financial Results
Strong pipeline of opportunities across all three strategic pillars WINNIPEG, Manitoba, Aug. 26, 2021 (GLOBE…
Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern
Exclusive license for MPro inhibitors supports rapidly growing small molecule development portfolio for combating COVID-19….
UPDATE – SOPHiA GENETICS to Report Second Quarter 2021 Financial Results on September 9, 2021
BOSTON and LAUSANNE, Switzerland, Aug. 26, 2021 (GLOBE NEWSWIRE) — SOPHiA GENETICS SA (Nasdaq: SOPH)…
Sorrento Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device
Sorrento’s mRNA vaccine (“STI-mRNA”) delivered with the MuVaxx™ Lymphatic Drug Delivery Device (“MuVaxx”), at 1/10th…
MDxHealth Reports Half Year 2021 Results
NEWS RELEASE – REGULATED INFORMATION26 AUGUST 2021, 18:00 CET MDxHealth Reports Half Year 2021 Results…
OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
Clinical trial sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by…
Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN
Preclinical studies show enhanced brain uptake of progranulin can be achieved using Denali’s Transport Vehicle…
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
Company sees a significant market opportunity for reference lab agreements to identify which variant is…
Gracell Biotechnologies to Participate in Upcoming Virtual Investor Conferences in September
SUZHOU, China and PALO ALTO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc….
Rakovina Therapeutics Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, Aug. 26, 2021 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV), a…
Ceapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational Highlights
– Company continues to increase R&D activities to advance clinical and preclinical programs – – Second…
Balstilimab Monotherapy Data Published in Gynecologic Oncology
Objective response rate of 20% and median duration of response not reached with 14.6 month…
SOPHiA GENETICS to Report Second Quarter 2021 Financial Results on September 9, 2021
BOSTON and LAUSANNE, Switzerland, Aug. 26, 2021 (GLOBE NEWSWIRE) — SOPHiA GENETICS SA (Nasdaq: SOPH)…